Thomas, Sunil
Dilbarov, Nickey
Kelly, Joseph
Mercogliano, Giancarlo
Prendergast, George C.
Funding for this research was provided by:
Sharpe Strumia Research Foundation (SSRF2021-06, SSRF2021-06, SSRF2021-06, SSRF2021-06, SSRF2021-06)
Article History
Received: 21 April 2023
Accepted: 16 July 2023
First Online: 21 July 2023
Competing interests
: S.T. and G.C.P. are faculty inventors of IBD treatment technology that is based on the use of Bin1 monoclonal antibody therapy, as described in U.S. Patent No. 10,494,424 and other related pending patents that are assigned to the Lankenau Institute for Medical Research. All other authors have no competing interests.